CTLA4 and neoplasm: The anti-tumor efficacy of anti-CTLA-4 antibodies in patients has been correlated with several predictive and pharmacodynamic (PD) biomarkers, including non-synonymous tumor mutational burden, changes in the TCR repertoire upon treatment, correlations of general patient immune status as well as increased frequencies of FcγRIIIA-expressing non-classical monocytes and reduced intratumoral Treg cell infiltration [18, 20–22].